News
The FDA has granted fast track designation to nadunolimab for use in combination with gemcitabine and nab-paclitaxel to treat patients with previously untreated, metastatic PDAC with high IL1RAP ...
The FDA has accepted the application for lurbinectedin in combination with atezolizumab as first-line maintenance for ES-SCLC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback